S B Hanauer

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. pmc New steroids for IBD: progress report
    S B Hanauer
    Medicine and Clinical Pharmacology, University of Chicago, Pritzker School of Medicine, IL 60637, USA
    Gut 51:182-3. 2002
  2. pmc Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
    S B Hanauer
    University of Chicago School of Medicine, Chicago, USA
    Can J Gastroenterol 21:827-34. 2007
  3. doi request reprint Positioning biologic agents in the treatment of Crohn's disease
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 15:1570-82. 2009
  4. ncbi request reprint Medical therapy for ulcerative colitis 2004
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, University of Chicago, Illinois 60637, USA
    Gastroenterology 126:1582-92. 2004
  5. pmc Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago Hospital, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Gut 56:1181-3. 2007
  6. doi request reprint Medical management of Crohn's disease: treatment algorithms 2009
    Stephen B Hanauer
    Medicine and Clinical Pharmacology, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Ill 60637, USA
    Dig Dis 27:536-41. 2009
  7. doi request reprint Review article: evolving concepts in treatment and disease modification in ulcerative colitis
    S B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Chicago, IL 60637, USA
    Aliment Pharmacol Ther 27:15-21. 2008
  8. ncbi request reprint Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, IL 60637, USA
    Clin Gastroenterol Hepatol 2:542-53. 2004
  9. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006
  10. ncbi request reprint Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
    Stephen B Hanauer
    University of Chicago, IL 60637, USA
    Nat Clin Pract Gastroenterol Hepatol 1:26-31. 2004

Detail Information

Publications94

  1. pmc New steroids for IBD: progress report
    S B Hanauer
    Medicine and Clinical Pharmacology, University of Chicago, Pritzker School of Medicine, IL 60637, USA
    Gut 51:182-3. 2002
  2. pmc Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial
    S B Hanauer
    University of Chicago School of Medicine, Chicago, USA
    Can J Gastroenterol 21:827-34. 2007
    ..8 g/day is more effective than 2.4 g/day in patients with mildly to moderately active UC and in the subgroup with moderate disease...
  3. doi request reprint Positioning biologic agents in the treatment of Crohn's disease
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 15:1570-82. 2009
    ..Future studies are still needed to best identify predictors of response to individual agents with differing mechanisms of action, as well as to optimize the risk-benefit of long-term maintenance therapy...
  4. ncbi request reprint Medical therapy for ulcerative colitis 2004
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, University of Chicago, Illinois 60637, USA
    Gastroenterology 126:1582-92. 2004
    ..Recent data regarding potential chemoprevention in long-standing ulcerative colitis and management of postoperative complications and pouchitis will also be discussed...
  5. pmc Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago Hospital, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Gut 56:1181-3. 2007
    ..The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies...
  6. doi request reprint Medical management of Crohn's disease: treatment algorithms 2009
    Stephen B Hanauer
    Medicine and Clinical Pharmacology, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, Ill 60637, USA
    Dig Dis 27:536-41. 2009
    ..Treatment should be optimized according to the patient status and response with whichever level of therapy is introduced and maintained...
  7. doi request reprint Review article: evolving concepts in treatment and disease modification in ulcerative colitis
    S B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Chicago, IL 60637, USA
    Aliment Pharmacol Ther 27:15-21. 2008
    ..More than two-thirds of ulcerative colitis patients experience at least one relapse over a period of 10 years. Treatments that reduce the likelihood of relapses also reduce the risk of long-term complications...
  8. ncbi request reprint Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, IL 60637, USA
    Clin Gastroenterol Hepatol 2:542-53. 2004
    ..The effect of different treatment regimens on antibody responses to infliximab and their clinical significance was examined by using data from ACCENT I...
  9. ncbi request reprint Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Illinois 60637, USA
    Gastroenterology 130:323-33; quiz 591. 2006
    ..A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD...
  10. ncbi request reprint Update on the etiology, pathogenesis and diagnosis of ulcerative colitis
    Stephen B Hanauer
    University of Chicago, IL 60637, USA
    Nat Clin Pract Gastroenterol Hepatol 1:26-31. 2004
    ..Patients who remain indeterminate between ulcerative colitis and Crohn's disease also continue to be a diagnostic challenge...
  11. ncbi request reprint Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis
    S B Hanauer
    Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Aliment Pharmacol Ther 24:37-40. 2006
    ..6 g/day of mesalazine, although the absence of dose-related side effects allows continuation of the same inductive dose through maintenance treatment without dose-related toxicity...
  12. doi request reprint The role of biologics in ulcerative colitis
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    Dig Dis 28:497-500. 2010
    ..Other biological agents that have targeted T cells such as visiluzimab and abatacept were not demonstrated to be effective in controlled trials...
  13. ncbi request reprint Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
    Stephen B Hanauer
    Section of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Inflamm Bowel Dis 12:S3-9. 2006
    ..Elucidation of immunological and genetic factors indicate multiple points at which the inflammatory cascade may be interrupted, yielding the possibility of precise, targeted therapies for IBD...
  14. ncbi request reprint The state of the art in the management of inflammatory bowel disease
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Rev Gastroenterol Disord 3:81-92. 2003
    ..Currently, a broad range of options allows physicians to tailor treatment to each patient's needs and preferences. Such considerations are essential for maximizing adherence to therapy...
  15. doi request reprint Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Y Leung
    Section of Gastroenterology and Nutrition, University of Chicago, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
    Gastroenterol Clin Biol 33:S202-8. 2009
    ..The ability to monitor thiopurine metabolites may make it possible to optimize therapeutic response by guiding clinicians on dose escalation...
  16. ncbi request reprint Controversies with aminosalicylates in inflammatory bowel disease
    Wee Chian Lim
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:104-17. 2004
    ....
  17. pmc Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1
    J H Cho
    The Emma Getz Inflammatory Bowel Disease Research Center, Department of Medicine, The University of Chicago Hospitals, 5841 S Maryland Avenue, MC6084, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 95:7502-7. 1998
    ..Thirteen additional loci demonstrated nominal (MLod > 1.0, P < 0.016) evidence for linkage. This screen provides strong evidence that there are several major susceptibility loci contributing to the genetic risk for CD and UC...
  18. ncbi request reprint Emerging biologic therapies in inflammatory bowel disease
    Wee Chian Lim
    Section of Gastroenterology, Department of Medicine, University of Chicago Hospitals, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:66-85. 2004
    ..Undoubtedly, with the success of infliximab, the role of biologic therapy will continue to expand in the future treatment of IBD...
  19. ncbi request reprint Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial
    Stephen B Hanauer
    Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 100:2478-85. 2005
    ..6 g/day. Whether 4.8 g/day of mesalamine (dosed with an investigational 800 mg tablet) is more effective than Asacol 2.4 g/day (dosed with a 400 mg tablet) in patients with moderately active ulcerative colitis is unknown...
  20. ncbi request reprint Update on medical management of inflammatory bowel disease: ulcerative colitis
    S B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Pritzker School of Medicine, Chicago, IL, USA
    Rev Gastroenterol Disord 1:169-76. 2001
    ..As further investigations continue to discern microbiological and immunoinflammatory targets, future therapies may include both probiotics and novel biological agents...
  21. ncbi request reprint Evolving treatment strategies for inflammatory bowel disease
    S B Hanauer
    Department of Medicine, Section of Gastroenterology, University of Chicago, Chicago, Illinois, USA
    Annu Rev Med 52:299-318. 2001
    ..The combination of conventional and novel approaches now offers the potential of modifying the natural history of these diseases...
  22. ncbi request reprint Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum
    Keri A Kles
    Martin Boyer Laboratories, The University of Chicago IBD Research Center, Chicago, IL, USA
    Inflamm Bowel Dis 11:253-7. 2005
    ..The present study tested the hypothesis that the use of all compounds with azo linkages leads to increased secretion...
  23. ncbi request reprint Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial
    E D Ehrenpreis
    Department of Gastroenterology, University of Chicago Hospitals, Chicago, IL 60637, USA
    Gastroenterology 117:1271-7. 1999
    ..Inhibition of tumor necrosis factor is a proposed mechanism for the anti-inflammatory properties of thalidomide. We performed an open-label trial of thalidomide in refractory Crohn's disease...
  24. ncbi request reprint Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
    M P Sparrow
    Section of Gastroenterology, University of Chicago Medical Center, Chicago, IL 60637, USA
    Aliment Pharmacol Ther 22:441-6. 2005
    ....
  25. pmc Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastroenterology 134:688-95. 2008
    ..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)...
  26. ncbi request reprint Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Rev Gastroenterol Disord 4:S18-24. 2004
    ..This review discusses the results of controlled clinical trials of anti-TNF agents for Crohn's disease...
  27. ncbi request reprint Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions
    Shamita B Shah
    Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S3-10. 2007
    ..Concomitant use of loperamide with diphenoxylate and atropine should be avoided in early pregnancy...
  28. doi request reprint Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease
    S B Hanauer
    University of Chicago, IL 60637, USA
    Aliment Pharmacol Ther 32:384-93. 2010
    ..In PRECiSE 2, patients were also eligible for enrolment if prior infliximab therapy was terminated due to loss of response...
  29. ncbi request reprint COLAL-PRED Alizyme
    Stephen B Hanauer
    University of Chicago Medical Center, Department of Medicine, Gastroenterology and Nutrition, MC 9028, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Curr Opin Investig Drugs 5:1192-7. 2004
    ..Alizyme expect to initiate a phase III trial in 2005...
  30. ncbi request reprint Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis
    David T Rubin
    The Reva and David Logan Center for Research in Gastrointestinal Diseases, University of Chicago, Chicago, Illinois, USA
    Clin Gastroenterol Hepatol 4:1346-50. 2006
    ..Aminosalicylates have been suggested as chemopreventive agents for colorectal cancer (CRC) in ulcerative colitis (UC). We studied the effect of aminosalicylate use on dysplasia and CRC risk in chronic UC...
  31. ncbi request reprint Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
    ..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after resection and ileocolic anastomosis...
  32. ncbi request reprint Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease
    Fernando A Navarro
    Division of Pediatric Gastroenterology, University of Chicago, Chicago, IL, USA
    J Pediatr Gastroenterol Nutr 45:312-8. 2007
    ....
  33. ncbi request reprint Crohn's disease: step up or top down therapy
    Stephen B Hanauer
    University of Chicago, 5841 S Maryland Ave, MC4076, Chicago, IL 60637, USA
    Best Pract Res Clin Gastroenterol 17:131-7. 2003
    ..Evidence for therapeutic efficacy in Crohn's disease is presented as a prologue to considerations necessary to determine the benefits and risks of early aggressive treatment versus sequential approaches based upon disease severity...
  34. ncbi request reprint Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials
    Stephen B Hanauer
    University of Chicago Pritzker School of Medicine, Illinois, USA
    Clin Gastroenterol Hepatol 2:379-88. 2004
    ..The aim of this study was to perform a meta-analysis of the efficacy results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine (Pentasa) for the acute treatment of mild to moderate Crohn's disease...
  35. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...
  36. ncbi request reprint Treatment of inflammatory bowel disease: safety and tolerability issues
    Fernando Navarro
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Am J Gastroenterol 98:S18-23. 2003
    ..The well-recognized multitude of adverse effects from corticosteroids are eliminated or minimized when rapidly metabolized steroids, such as budesonide, are used...
  37. ncbi request reprint Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort
    Stephen B Hanauer
    Section of Gastroenterology and Nutrition, University of Chicago, Chicago, IL 60637, USA
    Curr Med Res Opin 23:1033-43. 2007
    ....
  38. ncbi request reprint Biologics in peri-operative management of Crohn's disease
    S B Hanauer
    University of Chicago Hospital, Department of Gastroenterology, University of Chicago Pritzker School of Medicine, Chicago, USA
    Acta Gastroenterol Belg 64:191-2. 2001
    ..Post-operative trials are certainly needed to ascertain the impact on the inevitability of disease recurrence...
  39. ncbi request reprint Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
    S V Kane
    Department of Medicine, University of Chicago, Illinois, USA
    Am J Gastroenterol 96:2929-33. 2001
    ..46 [0.39-0.57]). CONCLUSION: Nonadherence is associated with multiple concomitant medications, male gender, and single status. These patient characteristics may be helpful in targeting those patients at higher risk for nonadherence...
  40. ncbi request reprint Review article: the long-term management of ulcerative colitis
    S B Hanauer
    Section of Gastroenterology, University of Chicago, IL 60637, USA
    Aliment Pharmacol Ther 20:97-101. 2004
    ....
  41. ncbi request reprint Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?
    David T Rubin
    The Reva and David Logan Gastrointestinal Clinical Research Center at the University of Chicago, Chicago, Illinois 60637, USA
    Gastrointest Endosc 65:998-1004. 2007
    ..Given the imperfect nature of this random approach, recent work has focused on improved surveillance techniques and suggests that neoplasia is endoscopically visible in many patients...
  42. ncbi request reprint Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine
    Miles P Sparrow
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, Illinois, USA
    Clin Gastroenterol Hepatol 5:209-14. 2007
    ..We describe the use of allopurinol in AZA/6-MP nonresponders to deliberately shunt metabolism of 6-MP toward 6-thioguanine (6-TGN) and improve clinical responses...
  43. ncbi request reprint Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease
    Andrew S Ross
    Department of Surgery, University of Chicago, IL, USA
    Nat Clin Pract Gastroenterol Hepatol 2:281-5; quiz 1 p following 285. 2005
    ..Azathioprine was added to the treatment regimen and the patient tapered off prednisone. At this stage the patient continued to do well clinically up until presentation...
  44. doi request reprint Management of Crohn's disease in adults
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 104:465-83; quiz 464, 484. 2009
    ..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time...
  45. ncbi request reprint General principles and pharmacology of biologics in inflammatory bowel disease
    Patricia L Kozuch
    Division of Gastroenterology, Department of Medicine, University of Chicago Hospitals, MC 4076, 5841 South Maryland Avenue, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 35:757-73. 2006
    ....
  46. ncbi request reprint Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease
    Stephen B Hanauer
    Section of Gastroenterology, University of Chicago, USA
    Am J Gastroenterol 100:1438-9. 2005
  47. ncbi request reprint The case for using 5-aminosalicyclates in Crohn's disease: pro
    Stephen B Hanauer
    Department of Medicine and Clinical Pharmacology, University of Chicago, Chicago, Illinois, USA
    Inflamm Bowel Dis 11:609-12. 2005
    ..Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD...
  48. ncbi request reprint Review article: aminosalicylates in inflammatory bowel disease
    S B Hanauer
    University of Chicago, Section of Gastroenterology, IL 60637, USA
    Aliment Pharmacol Ther 20:60-5. 2004
    ..The maintenance benefits of mesalazine appear to be limited to patients 'induced into remission' with mesalazine and in some post-operative settings...
  49. ncbi request reprint New lessons: classic treatments, expanding options in ulcerative colitis
    S B Hanauer
    University of Chicago, Section of Gastroenterology, Chicago, Illinois 60637, USA
    Colorectal Dis 8:20-4. 2006
    ..4 g. The evidence provided by the ASCEND studies support the rationale for a 'top-down' dosing strategy for UC where more potent therapies are introduced at an earlier stage of moderately severe disease...
  50. ncbi request reprint Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease
    J H Cho
    The Martin Boyer Genetics Research Laboratories, Section of Hematology, Department of Medicine, The University of Chicago Hospital, 5841 South Maryland Avenue, MC6084, Chicago, IL 60637, USA
    Hum Mol Genet 9:1425-32. 2000
    ..These findings provide a unique opportunity to refine the localization and identify a major susceptibility gene for a complex genetic disorder...
  51. ncbi request reprint Mesalamine derivatives in the treatment of Crohn's disease
    Laura E Harrell
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 33:303-17, ix-x. 2004
    ....
  52. ncbi request reprint The role of loperamide in gastrointestinal disorders
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 8:15-20. 2008
    ..Loperamide is generally well tolerated at recommended nonprescription doses, with the most common side effects related to the impact on bowel motility (abdominal pain, distention, bloating, nausea, vomiting, and constipation)...
  53. ncbi request reprint Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down"
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S17-22. 2007
    ....
  54. ncbi request reprint Refining the role of TNF antagonists for Crohn's disease. Introduction
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S1-2. 2007
  55. ncbi request reprint The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction
    Stephen B Hanauer
    Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Rev Gastroenterol Disord 7:S1-2. 2007
  56. ncbi request reprint Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation
    Sunanda V Kane
    University of Chicago, Chicago, Illinois 60637, USA
    Am J Gastroenterol 98:1309-14. 2003
    ..The aim of this study was to determine the sensitivity and specificity of fecal lactoferrin concentrations for inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) versus healthy controls...
  57. ncbi request reprint A lupus-like syndrome associated with infliximab therapy
    Jason B Klapman
    Section of Gastroenterology, Department of Medicine, University of Chicago, IL, USA
    Inflamm Bowel Dis 9:176-8. 2003
    ..Infliximab therapy may cause a lupus-like syndrome that is reversible upon discontinuing this agent. These findings support recent evidence identifying TNF-alpha as an inhibitor of autoantibody formation...
  58. ncbi request reprint Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 101:1030-8. 2006
    ..Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs)...
  59. ncbi request reprint Medical treatment of Crohn's disease
    Janet Harrison
    Department of Medicine and Clinical Pharmacology, Section of Gastroenterology and Nutrition, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Gastroenterol Clin North Am 31:167-84, x. 2002
    ..Patients do, however, live a normal life span. The goal of therapy is to optimize the quality of life, minimize disease activity and disease-related complications, and avoid therapeutic toxicity...
  60. ncbi request reprint Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation
    Laura E Harrell
    Section of Gastroenterology and Nutrition, University of Chicago, IL, USA
    Nat Clin Pract Gastroenterol Hepatol 1:113-6; quiz 1 p following 116. 2004
    ..Ultimately, a CT scan revealed marked thickening of the distal ileum and confirmed diagnosis of an abscess in continuity with the inflamed bowel...
  61. pmc Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis
    Joel R Pekow
    University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Chicago, Illinois, USA
    Inflamm Bowel Dis 16:1352-6. 2010
    ..The management of low-grade (LGD) and indefinite dysplasia (IND) in patients with ulcerative colitis (UC) remains controversial, as outcomes after a diagnosis of LGD or IND in previous studies vary widely...
  62. doi request reprint Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease
    W J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, CA 92093 0956, USA
    Aliment Pharmacol Ther 38:255-63. 2013
    ..Recent evidence suggests that embryonated eggs of the porcine whipworm Trichuris suis ova (TSO) may be an effective treatment for inflammatory bowel disease (IBD)...
  63. pmc Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study
    F Michelassi
    Departments of Surgery, Medicine, Radiology, and Pathology, University of Chicago, Chicago, Illinois 60637, USA
    Ann Surg 232:401-8. 2000
    ..To report on the results of a prospective longitudinal study of a new bowel-sparing procedure (side-to-side isoperistaltic strictureplasty [SSIS]) in patients with extensive Crohn's disease...
  64. ncbi request reprint Crohn's disease therapy: step up or top down therapy
    S B Hanauer
    University of Chicago Hospital, Department of Gastroenterology, University of Chicago Pritzker School of Medicine, Chicago, USA
    Acta Gastroenterol Belg 64:189-90. 2001
    ..The potential of aggressive initial therapy followed by step-down maintenance therapy affords the potential to modify the disease course, a possibility that has not been accomplished by current therapeutic algorithims...
  65. ncbi request reprint Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage
    Richard H Duerr
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
    Hum Mol Genet 11:2599-606. 2002
    ..12). Thus, the existence of an inflammatory bowel disease locus on chromosome 3p26 is supported by significant linkage, transmission/disequilibrium and partitioning of linkage evidence...
  66. ncbi request reprint Considerations in the management of steroid-dependent Crohn's disease
    Loren Laine
    Sectioin of Gastroenterology and Nutrition, University of Chicago, Chicago, Illinois 60637, USA
    Gastroenterology 125:906-10. 2003
  67. pmc African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity
    James P Lodolce
    Department of Medicine, University of Chicago, Chicago, IL 60612, USA
    J Immunol 184:7001-9. 2010
    ..This is the first report of an association between TNFAIP3 polymorphisms and autoimmunity in African-Americans...
  68. ncbi request reprint Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis
    Stephen B Hanauer
    Am J Gastroenterol 98:215-6. 2003
  69. ncbi request reprint Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Intern Med 146:829-38. 2007
    ..No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent...
  70. ncbi request reprint Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States
    William J Tremaine
    Inflammatory Bowel Disease Clinic, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:1748-54. 2002
    ..In four previous controlled trials in Crohn's disease, remission rates ranged from 51% to 69%. We sought to evaluate the efficacy and safety of this drug in a population of patients in the United States with Crohn's disease...
  71. ncbi request reprint Infliximab in the treatment of Crohn's disease: a user's guide for clinicians
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 97:2962-72. 2002
    ..Patients with evidence of active infection should not receive infliximab until the infection is adequately treated, and all patients should be screened for tuberculosis prior to initiating infliximab therapy...
  72. pmc Treatment of inflammatory bowel disease: a review of medical therapy
    Patricia L Kozuch
    Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    World J Gastroenterol 14:354-77. 2008
    ..Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC...
  73. ncbi request reprint A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  74. doi request reprint Mea culpa
    Stephen B Hanauer
    Nat Clin Pract Gastroenterol Hepatol 5:409. 2008
  75. ncbi request reprint Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt
    Stephen B Hanauer
    Am J Gastroenterol 98:697-8. 2003
  76. ncbi request reprint Immunogenicity of infliximab in Crohn's disease
    Stephen B Hanauer
    N Engl J Med 348:2155-6; author reply 2155-6. 2003
  77. ncbi request reprint Maintenance therapy with certolizumab pegol for Crohn's disease
    Stefan Schreiber
    Hospital for General Internal Medicine, Christian Albrechts University, Kiel, Germany
    N Engl J Med 357:239-50. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment with a high binding affinity for tumor necrosis factor alpha that does not induce apoptosis of T cells or monocytes...
  78. ncbi request reprint Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  79. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  80. ncbi request reprint Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty
    Stephen B Hanauer
    Nat Clin Pract Gastroenterol Hepatol 2:493. 2005
  81. ncbi request reprint Treatment of Crohn's disease: the "long" of it
    Stephen B Hanauer
    Gastroenterology 128:2164-6. 2005
  82. ncbi request reprint Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastrointest Endosc 63:433-42; quiz 464. 2006
    ....
  83. ncbi request reprint Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus
    Jean Paul Achkar
    Center for Inflammatory Bowel Disease, Department of Gastroenterology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Am J Gastroenterol 101:572-80. 2006
    ..The purpose of this study was to assess phenotypic subsets that contribute to the major IBD susceptibility loci...
  84. ncbi request reprint Infliximab or cyclosporine for severe ulcerative colitis
    Stephen B Hanauer
    Gastroenterology 129:1358-9; author reply 1359. 2005
  85. ncbi request reprint Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Gastroenterol 40:482-9. 2006
    ....
  86. ncbi request reprint Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Inflamm Bowel Dis 10:S2-10. 2004
    ..Here we also evaluate the current preferable treatment practices, based on scientifically valid research and collective clinical experience, for the management of mild to moderate Crohn's disease...
  87. ncbi request reprint Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
    Bruce E Sands
    Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 13:2-11. 2007
    ..Natalizumab, a humanized monoclonal IgG(4) antibody to alpha4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied...
  88. ncbi request reprint A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis
    Stefan Schreiber
    Department of General Internal Medicine, Christian Albrechts University, Schittenhelmstrasse 12, Kiel Schleswig Holstein 24105, Germany
    Gastroenterology 132:76-86. 2007
    ..Tetomilast (OPC-6535), a novel thiazole compound, inhibits phosphodiesterase-4 and proinflammatory functions of leukocytes including superoxide production and cytokine release...
  89. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  90. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
    ..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice...
  91. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
    ..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)...
  92. ncbi request reprint Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    Jean Frederic Colombel
    Department of Hepatogastroenterology, Hopital Claude Huriez, Centre Hospitalier Universitaire de Lille, Rue Michel Polonovski, 59037 Lille, France
    Gastroenterology 132:52-65. 2007
    ....
  93. ncbi request reprint Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study
    Kim L Isaacs
    University of North Carolina, Chapel Hill, North Carolina 27599 7032, USA
    Inflamm Bowel Dis 13:1250-5. 2007
    ..The efficacy of the nonabsorbable antibiotic rifaximin in patients with active acute or chronic pouchitis is unknown...
  94. ncbi request reprint Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials
    William J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1780-7. 2005
    ..To evaluate the efficacy and safety of oral budesonide for maintenance of remission in patients with mild to moderately active Crohn's disease (CD) of the ileum and/or ascending colon...